Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69).
Watkins
Claire
C
Rukazenkov
Yuri
Y
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors